Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7051 to 7065 of 7679 results

  1. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued [GID-TA10334]

  2. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued [GID-TA10616]

  3. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    In development [GID-TA10502] Expected publication date: TBC

  4. Non-invasive skin closure devices for surgical incisions (MT775)

    In development [GID-MT593] Expected publication date: TBC

  5. Surgical vessel sealing systems (MT798)

    In development [GID-MT594] Expected publication date: TBC

  6. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development [GID-HST10020] Expected publication date: TBC

  7. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued [GID-TA10490]

  8. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    In development [GID-TA10525] Expected publication date: TBC

  9. Haemochromatosis

    Discontinued [GID-NG10287]

  10. Acute bowel obstruction

    Discontinued [GID-NG10377]

  11. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued [GID-NG10385]

  12. Breathlessness

    Discontinued [GID-NG10387]

  13. Atopic Dermatitis (Eczema)

    Discontinued [GID-NG10289]

  14. Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]

    In development [GID-TA10391] Expected publication date: TBC